Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Fortis Healthcare Limited — Q3 FY24
Fortis Healthcare reported a satisfactory Q3 FY24 with consolidated revenue of INR 1,680 crore (+8% YoY) and operating EBITDA margin of 16.9% (down 80bps YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare reported a satisfactory Q3 FY24 with consolidated revenue of INR 1,680 crore (+8% YoY) and operating EBITDA margin of 16.9% (down 80bps YoY). Hospital business revenue grew 10% YoY to INR 1,389 crore, with EBITDA margin expanding to 18% (+130bps YoY) driven by cost optimization and a shift to high-complexity procedures. ARPOB grew 10.6% YoY to INR 2.23 crore. Occupancy dipped to 64% due to seasonal factors and bed additions, but management expects recovery to ~70% in Q4. Brownfield expansion of ~2,200 beds over four years and divestment of loss-making Chennai facilities support margin trajectory toward 20% by year-end and 25% over 3-4 years. Key risk: slower-than-expected ramp-up of new beds and occupancy, which could delay margin expansion.
फोर्टिस हेल्थकेयर ने तीसरी तिमाही में 1,680 करोड़ रुपये की कमाई की, जो पिछले साल से 8% ज्यादा है। कंपनी का मुनाफा मार्जिन 16.9% रहा, जो थोड़ा कम हुआ है। अस्पतालों का कारोबार 10% बढ़कर 1,389 करोड़ रुपये हो गया। लागत घटाने और मुश्किल इलाजों पर ध्यान देने से मार्जिन 18% तक पहुंच गया। हर बिस्तर से कमाई 10.6% बढ़कर 2.23 करोड़ रुपये हो गई। मरीजों की संख्या 64% रही, लेकिन अगली तिमाही में 70% होने की उम्मीद है। कंपनी अगले चार साल में 2,200 नए बिस्तर जोड़ेगी और घाटे के अस्पताल बेचेगी। इससे मार्जिन साल के अंत तक 20% और 3-4 साल में 25% हो सकता है। खतरा: नए बिस्तरों से कमाई धीमी हो सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Occupancy ramp-up may be slower than expected
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Occupancy
64%
-2pp YoY
Occupancy declined due to seasonal impact and addition of 100 operational beds; like-to-like occupancy was stable.
ARPOB
INR 2.23 crore
+10.6% YoY
Growth driven by shift to higher complexity procedures; management expects ARPOB growth to moderate to ~5%.
Hospital EBITDA Margin
18%
+130bps YoY
Hospital business margin improved due to operational efficiency and cost optimization; target 20% by year-end.
International Patient Revenue
INR 113 crore
Flat YoY
Flat due to geopolitical issues in Middle East; recovery seen in Jan-Feb 2024.
What Changed vs Last Quarter
NEW
Occupancy expected to trend toward 70% in coming quarters
Management expects occupancy to recover to ~70% in Q4 FY24 and next year, driven by seasonal recovery and international patient rebound.
UPDATED
Hospital EBITDA margin target of 20% by end of FY24
Management expects to achieve 20% EBITDA margin for the hospital business by year-end, driven by occupancy improvement and cost optimization.
UPDATED
Long-term hospital EBITDA margin target of 25% in 3-4 years
Over the next 3-4 years, as brownfield bed expansions ramp up, management aims for 25% EBITDA margin.
UPDATED
~2,200 brownfield beds over next 4 years
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
DROPPED
70% occupancy exit rate in FY24
The company expects to exit FY24 with occupancy around 70%, despite seasonal fluctuations and new bed additions.
DROPPED
250 beds to be added in FY24
Brownfield expansions at Mulund, Anandapur, BG Road, and Ludhiana will add approximately 250 beds in the current financial year.
NEW RISK
Occupancy ramp-up may be slower than expected
New bed additions could dilute occupancy, delaying margin expansion. Management acknowledged this but expects gradual ramp-up.
NEW RISK
International patient revenue vulnerable to geopolitical shocks
Flat international revenue in Q3 due to Middle East tensions; recovery seen but risks remain from geopolitical instability.
NEW RISK
Low-margin hospitals may take longer to turn around
~950 beds in hospitals with <10% EBITDA margin; structural improvements like adding specialties will take 2-3 years.
NEW RISK
Clinician attrition at key hospitals
FMRI Gurgaon saw a premium cardiac clinician depart, impacting Q3 performance. New clinician expected to join in Q4.
RISK GONE
Legal and professional costs overhang
Elevated legal costs of INR 6-7 crore in Q2 due to ongoing litigation; timing of resolution is uncertain and could continue to pressure margins.
RISK GONE
Doctor cost inflation and talent churn
Analyst raised concern about rising guaranteed payouts for clinicians; management acknowledged some churn but deemed risk low. However, cost pressures could impact margin trajectory.
RISK GONE
Delays in bed commissioning
Management identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
RISK GONE
Low-margin oncology mix drags margins
Rapid growth in medical oncology (lower margin) relative to surgical oncology could cap margin expansion despite absolute EBITDA growth.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Management identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
Mentioned in Q1 FY24, Q2 FY24
Rapid growth in medical oncology (lower margin) relative to surgical oncology could cap margin expansion despite absolute EBITDA growth.
Fast read
Guidance and risk preview
Management expects to achieve 20% EBITDA margin for the hospital business by year-end, driven by occupancy improvement and cost optimization.
New bed additions could dilute occupancy, delaying margin expansion.
View Risks →